{Reference Type}: Journal Article
{Title}: Diagnostic performance of multiplex lateral flow tests in ambulatory patients with acute respiratory illness.
{Author}: Murphy C;Mak L;Cheng SMS;Liu GYZ;Chun AMC;Leung KKY;Sum NYW;Poukka E;Peiris M;Cowling BJ;
{Journal}: Diagn Microbiol Infect Dis
{Volume}: 110
{Issue}: 1
{Year}: 2024 Sep 4
{Factor}: 2.983
{DOI}: 10.1016/j.diagmicrobio.2024.116421
{Abstract}: We assessed the performance of three different multiplex lateral flow assays manufactured by SureScreen, Microprofit and Goldsite which provide results for influenza, respiratory syncytial virus (RSV) and SARS-CoV-2. Between 4 April and 20 October 2023, 1646 patients 6 months and older presenting to an outpatient department of a hospital in Hong Kong with ≥2 symptoms or signs of an acute respiratory illness were enrolled. The point estimates for all three multiplex tests had sensitivity >80% for influenza A and SARS-CoV-2 compared to PCR, and the tests manufactured by Microprofit and Goldsite had sensitivity >84% to detect RSV. Specificity was >97% for all three tests except for the SureScreen test which had specificity 86.2% (95% CI: 83.9% to 88.3%) for influenza A. Sensitivity was lower than reported by the manufacturers, resulting in a higher risk of false negatives. The three multiplex tests performed better in patients with high viral loads.